FDA warns Estar Technologies over selling seven unapproved PRP/PRF device kits in the U.S. without clearance or approval.
What happened
FDA found the issue by reviewing Estar's websites, tropocells.com and estar-medical.com, in April 2026. FDA said the firm was offering seven PRP/PRF device kits for sale in the U.S. without premarket approval (PMA) or an investigational device exemption (IDE — permission to study an unapproved device in humans). FDA also said website claims for the Tropocells PRP kit go beyond its cleared 510(k) (premarket notification) indication and require a new notification.
What FDA found
Estar offered seven PRP/PRF device kits for sale in the U.S. without FDA premarket approval (PMA) or an approved investigational device exemption (IDE).
Section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B); section 515(a), 21 U.S.C. § 360e(a); section 520(g), 21 U.S.C. § 360j(g)Estar did not notify FDA before commercially distributing the devices, as required by the 510(k) premarket notification process.
Section 502(o), 21 U.S.C. § 352(o); section 510(k), 21 U.S.C. § 360(k); 21 CFR 807.81(a)Estar's website claims for the Tropocells PRP kit expand its use beyond the cleared indication, a major change that requires a new 510(k) notification.
21 CFR 807.81(a)(3)Introducing these illegally marketed devices — called adulterated or misbranded — into interstate commerce is a prohibited act.
Section 301(a), 21 U.S.C. § 331(a)
What FDA wants
FDA tells Estar to stop activities that make the devices misbranded or adulterated, including commercial distribution for the cited uses. Estar must answer in writing within 15 business days with the steps taken, supporting documents, and a timetable for any work not finished.
Who should pay attention
- U.S. clinics and clinicians considering PRP/PRF kits for unapproved uses
- distributors and importers of Estar or similar PRP/PRF devices
- manufacturers relying on a limited 510(k) clearance while marketing broader indications
This is a summary. Read the original letter on fda.gov.